1
Pharmaceutical Composition Comprising a GLP-1-Agonist and Methionine. May 16, 2019: US20190142747-A1

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates wher ...


2
Antibodies With High Affinity For Alpha-Klotho. May 16, 2019: US20190145976-A1

An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof specifically binds to an epitope of a αKlotho polypeptide, optionally a folded αKlotho or optionally with a dissociation constant (KD) of about 2 nM or less, as measured by competitive ELISA assay, meth ...


3
INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE. PIONEER HI BRED INTERNATIONAL, May 16, 2019: US20190142013-A1

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus ...


4
THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY. May 16, 2019: US20190145984-A1

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide ...


5
PRO-PIGMENTING PEPTIDES. Sederma, May 16, 2019: US20190142723-A1

The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n≠0 —Xaa1 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phe ...


6
METHOD AND COMPOSITION FOR INCREASING CARDIAC INFLOW. May 16, 2019: US20190142902-A1

A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relax ...


7
COATINGS CONTAINING POLYMER MODIFIED ENZYME FOR STABLE SELF-CLEANING OF ORGANIC STAINS. May 16, 2019: US20190144709-A1

Bioactive coatings that are stabilized against inactivation by weathering are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to ...


8
Coatings Containing Polymer Modified Enzyme For Stable Self-Cleaning Of Organic Stains. May 16, 2019: US20190144710-A1

Bioactive coatings that are stabilized against inactivation by weathering are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to ...


9
Coatings Containing Polymer Modified Enzyme For Stable Self-Cleaning Of Organic Stains. May 16, 2019: US20190144711-A1

Bioactive coatings suitable for facilitating removal of a fingerprint when contacting the coating are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlay ...


10
SYSTEMS AND METHODS FOR SNP ANALYSIS AND GENOME SEQUENCING. NOBLIS, May 16, 2019: US20190146962-A1

In some embodiments, techniques for identifying one or more species in an undifferentiated environmental sample comprising a plurality of nucleic acid sequences are provided. One or more indices that represent a plurality of reference nucleic acid sequences may be provided, and data may be received ...